MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
31.75
+0.32 (1.02%)
At close: May 21, 2026, 4:00 PM EDT
31.79
+0.04 (0.13%)
After-hours: May 21, 2026, 4:01 PM EDT
MBX Biosciences Stock Forecast
Stock Price Forecast
The 11 analysts that cover MBX Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $61.4, which forecasts a 93.39% increase in the stock price over the next year. The lowest target is $18 and the highest is $88.
Price Target: $61.4 (+93.39%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for MBX Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 9 | 11 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $66 → $70 | Buy | Maintains | $66 → $70 | +120.47% | May 12, 2026 |
| Citizens | Citizens | Buy Maintains $76 → $86 | Buy | Maintains | $76 → $86 | +170.87% | May 12, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $50 → $70 | Strong Buy | Maintains | $50 → $70 | +120.47% | May 11, 2026 |
| Barclays | Barclays | Buy Initiates $66 | Buy | Initiates | $66 | +107.87% | Jan 28, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $77 → $88 | Strong Buy | Maintains | $77 → $88 | +177.17% | Jan 16, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.86
from -2.38
EPS Next Year
-3.70
from -2.86
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.44 | -3.13 | ||||||
| Avg | -2.86 | -3.70 | ||||||
| Low | -3.18 | -3.96 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.